Leukemia (ALL): Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Study Information

Purpose:
This study will have 2 groups: subjects who do not have the Philadelphia chromosome mutation (Ph-) and subjects who do have the mutation (Ph+). Treatments for the two groups will be different and are outlined below. In general, there are 3 main steps to all of the treatments. Induction/Re-Induction treatment is given first. It is a treatment given over a short period of time (usually only a few months) to get rid of as many of the leukemia cells as possible very quickly. Post-Remission treatment is given next. It is given to get rid of any leukemia cells that are left once your leukemia goes into remission and to make sure the leukemia cells don’t come back over a short period of time (usually only a few months). Maintenance treatment is given last. It is a lower dose treatment given over a long period of time (up to several years) to help keep the leukemia cells from coming back. Depending on which arm of the study you are on, Blinatumomab will be given as part of induction/re-induction or post-remission along with standard chemotherapy.

Lead Researcher (Principal Investigator)

Lead Researcher: Kristen O'Dwyer

Study Contact Information

Additional Study Details

Learn More About These Conditions

More information about Acute lymphoblastic leukemia [ALL]

Return to Search